Most of this research happens at night, after the person you are worried about has gone quiet, with you on your phone typing a question you would never say aloud in front of them.

If that is you, here is the most useful number we found. In our paid survey, 443 Midwest adults in ten states were asked what would really move someone to try ketamine-type treatment for depression or post-traumatic stress. Their own doctor's recommendation came first at 74 percent, with a close friend or relative next at 18 percent, then someone in uniform they follow online at 4 percent, an ad at 2 percent, and a podcast host at 1 percent.

The figures are final and validated. Below are six things caregivers often believe, set against what the data and the guardrails around this treatment support. None of it is medical advice, and only a clinician familiar with your person's history can say whether a treatment fits.

Belief one: if this treatment were real, their doctor would have brought it up by now

We measured public awareness. Spravato, an approved esketamine spray meant for depression that persists despite treatment, was a name 73 percent of respondents had never heard; another 21 percent knew the name but not the treatment, and 6 percent could explain it. Those are answers from the general public. We did not survey doctors or ask what doctors know, and nothing here speaks to any clinician's knowledge.

The honest takeaway is narrower: unfamiliarity is the normal state among ordinary people, so a topic like this usually has to be raised aloud. A fifteen-minute blood pressure follow-up will not drift toward treatment-resistant depression by itself. Silence in an exam room is usually an agenda nobody changed, not evidence.

Belief two: this gets decided on the internet

Your reading has value, but it is not where the decision lands. Asked where they would go first to pursue this treatment, 56 percent of respondents said the primary doctor, 23 percent a psychiatrist or other mental health clinician, and 12 percent an online search, while 5 percent could not name any first step at all.

That last group is the one you can help. Some people stall not because they decided against anything but because no first step is obvious. If you do nothing else this week, find out who your person's primary doctor is, whether they are still an active patient, and how that office takes appointment requests. Unglamorous work, and the real bottleneck.

Belief three: the right article will finally convince them

Caregivers collect evidence: a printout, a link, a recovery story. The instinct is generous but aimed at the wrong target. Ads moved 2 percent of respondents, podcast hosts 1, and someone they follow online 4. So the goal of anything you share is smaller than you think: not belief in a treatment, just willingness to say one sentence to a doctor. Aim there and the pressure drops for both of you.

Belief four: if you push hard enough, they will go

A friend's or relative's word would move 18 percent, which looks like defeat next to 74 percent for their own doctor. It is not. That is the second-strongest answer in the question, ahead of every media channel we tested combined. Your influence is real; it just gets spent badly on debating the treatment.

The influence that seems to matter is logistical. Ride along. Make the call while they are in the room. Write down the two questions they wanted to ask and hand them the paper. Say plainly that you are not asking them to agree to anything, only to ask. Advocacy that ends in an appointment beats persuasion that ends in an argument.

Belief five: clinic ketamine and mail-order ketamine are the same product

They are not, and this distinction is the one most worth carrying into any conversation. Spravato, an esketamine spray, won FDA approval for treatment-resistant depression on the condition that every dose happen under supervision in a certified office, with monitoring before the patient goes home, and the supervision comes with the approval rather than as an upsell. Ketamine arranged through telehealth and taken at home is a separate, far grayer market with different oversight. To see how a clinic offering the approved version explains it, Brain Recovery Centers has an overview of Spravato care.

Respondents cared about this even without the vocabulary. For 19 percent, FDA approval alone would settle it, and 40 percent more called it a big factor, 59 percent in all, and 27 percent ranked it among a provider's two most important traits. When you look at a program, ask early which of the two it is.

Belief six: you will have to pay cash to get anywhere

Many assume this is a cash-only world where speed is bought and coverage is a fantasy. Stated preference runs the other way. Offered insured care with more hoops or a faster start paid from their own pocket, half of respondents (51 percent) accepted the hoops, while paying drew 23 percent and indecision 26. Coverage also dominated provider choice: insurance landed among the top two priorities of 85 percent, and it would decide or weigh heavily for 65 percent.

So the coverage conversation is the main road, not a delay. Ask the prescribing office which treatments it bills, whether prior authorization is required, and which proof of past medication trials it expects, then ask the insurer the same from its side.

None of this says whether the treatment is right for the person you love; their clinician, with the diagnosis and treatment history in hand, decides that. What the data shows is where your effort goes furthest, and the answer is consistent: toward an appointment.

One more thing matters more than anything above. If the person you care for talks about not wanting to be here, or said something that frightened you, do not sit with it alone until morning. Dial or text 988 whenever you need it; the line welcomes worried relatives, not only the person in crisis.

Methodology

Pollfish survey 395586438 was commissioned and paid for by this publisher, and its fieldwork on the Pollfish panel ended June 23, 2026. The 443 people who took part were 18 to 64, drawn from ten Midwest states. Where a question accepted several selections, each is a share of respondents, so totals can top 100. The figures have passed the panel's final checks.

Beliefs caregivers hold about ketamine therapy that mislead